These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25134536)

  • 21. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast.
    Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W
    Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cafestol has a weaker inhibitory effect on osteoclastogenesis than kahweol and promotes osteoblast differentiation.
    Fukuma Y; Sakai E; Nishishita K; Okamoto K; Tsukuba T
    Biofactors; 2015; 41(4):222-31. PubMed ID: 26154488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation.
    Kong X; Wu W; Yang Y; Wan H; Li X; Zhong M; Zhao H; Su X; Jia S; Ju D; Lin N
    J Transl Med; 2015 Mar; 13():91. PubMed ID: 25889035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
    van Heerden B; Kasonga A; Kruger MC; Coetzee M
    Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
    Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
    J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.
    Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K
    Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-osteoclastogenic activity of matairesinol via suppression of p38/ERK-NFATc1 signaling axis.
    Choi SW; Park KI; Yeon JT; Ryu BJ; Kim KJ; Kim SH
    BMC Complement Altern Med; 2014 Jan; 14():35. PubMed ID: 24444335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
    Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
    Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATc1 activation.
    Wu L; Luo Z; Liu Y; Jia L; Jiang Y; Du J; Guo L; Bai Y; Liu Y
    Stem Cell Res Ther; 2019 Dec; 10(1):375. PubMed ID: 31805984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.
    Chiou WF; Liao JF; Huang CY; Chen CC
    Br J Pharmacol; 2010 Sep; 161(2):321-35. PubMed ID: 20735418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.